1. Clinical Trial: Heme Arginate in patients planned for Cardiac Surgery (HACS)
- Author
-
David C. Kluth, Vipin Zamvar, Rachel Thomas, Jeremy Hughes, and Fiona Duthie
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Ischemia ,Hemodynamics ,urologic and male genital diseases ,Gastroenterology ,chemistry.chemical_compound ,Internal medicine ,medicine ,Heme ,urogenital system ,business.industry ,Acute kidney injury ,Heme arginate ,General Medicine ,medicine.disease ,female genital diseases and pregnancy complications ,Cardiac surgery ,Porphyria ,chemistry ,Anesthesia ,Meeting Abstract ,Surgery ,Complication ,business ,Cardiology and Cardiovascular Medicine - Abstract
Acute kidney injury (AKI) is a significant complication of cardiac surgery and is associated with increased morbidity and mortality [1]. Despite much research, there is no specific therapy available. Although AKI can be multifactorial, ischaemia reperfusion injury (IRI) often plays a key role. Thus, cardiac surgery offers an attractive opportunity for translational AKI research given the predictive haemodynamic challenge to renal perfusion. Hemeoxygenase-1 (HO-1) is a key inducible anti-inflammatory enzyme that catalyses the breakdown of the pro-oxidant protein heme ubiquitously found at inflamed sites. The drug heme arginate has been in use for over 20 years in the treatment of porphyria but also upregulates HO-1 in peripheral blood mononuclear cells (PBMCs) [2] and ameliorates calf muscle ischaemia [3]. In addition, treatment of mice with heme arginate prior to renal IRI strongly upregulates renal HO-1 expression and protects from AKI [4]. We therefore hypothesise that HA may offer a prophylactic therapy for human renal IRI via the upregulation of HO-1.
- Published
- 2015